Alex Burgin joined the Broad Institute of MIT and Harvard in 2013 as the senior scientific advisor to the institute’s chief scientific officer (CSO), Todd Golub. An institute scientist at the Broad, Burgin works with the CSO to chart the Broad’s scientific course by establishing and facilitating scientific collaborations, developing new initiatives, and assessing existing research activities. Burgin also helps the CSO and the institute’s executive leadership team coordinate large multi-program projects and evaluate Institute goals and investments. Burgin also advises several of the institute’s drug discovery projects.
A scientist by training, Burgin has over 25 years’ experience spanning both academia and the private sector. Burgin completed his postdoctoral training at the National Institutes of Health, and was enzymology group leader at Ribozyme Pharmaceuticals prior to joining the faculty of San Diego State University, where he ran an active research program studying enzyme structure-function relationships. He then joined Emerald BioStructures (now Beryllium) where, as chief operating officer and then CSO, he led multiple drug discovery projects.
Burgin holds an A.B. from Wabash College and a Ph.D. in genetics from Indiana University.